Anas Nahhas, MD
Critical Care Medicine · Chicago Ridge, ILNPI 1780648873
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,600 of the $9,457 with a category attached, or 80.4%. It is spread thinly across 28 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,782, 6.8 times the $557 reported in 2019. Among critical care medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- GSK$2K
- AstraZeneca$2K
- Electromed, Inc.$717
- Jazz Pharmaceuticals Inc.$516
- Grifols USA, LLC$509
- plus $2K from 22 others
What the payments were for
- Consulting fees$1,58117%
- Food & beverage$7,60080%
- Education$2763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 19 | $1,942 |
| GSK | 134 | $1,834 |
| AstraZeneca | 51 | $1,713 |
| Electromed, Inc. | 54 | $717 |
| Jazz Pharmaceuticals Inc. | 12 | $516 |
| Grifols USA, LLC | 21 | $509 |
| Boehringer Ingelheim | 16 | $362 |
| Regeneron Healthcare Solutions, Inc. | 14 | $272 |
| Insmed, Inc. | 19 | $272 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $269 |
| Genentech USA, Inc. | 11 | $143 |
| Inspire Medical Systems, Inc. | 2 | $139 |
| Amgen | 6 | $138 |
| Merck | 6 | $107 |
| Inogen, Inc. | 5 | $85 |
| Novartis | 3 | $69 |
| Actelion Pharmaceuticals US, Inc. | 3 | $66 |
| Philips North America LLC | 3 | $57 |
| Lilly USA, LLC | 3 | $52 |
| Mylan Specialty L.p. | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Advanced Respiratory, Inc | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $21 |
| Baxter Healthcare | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,457 in reported general payments places this provider in the 90th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $217,441 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 223 | $193,754 |
| Pirfenidone | 12 | $107,561 |
| Dupixent PenDupilumab | 19 | $76,554 |
| XolairOmalizumab | 13 | $72,456 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $36,832 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $26,328 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $23,769 |
| Spiriva RespimatTiotropium Bromide | 22 | $13,688 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 197 | $6,648 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,352 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $3,688 |
| Montelukast Sodium | 139 | $1,993 |
| Azithromycin | 140 | $1,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,834 | $253,810341 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $362 | $231,12939 claims |
| AstraZenecaBreztri Aerosphere | $1,713 | $36,83261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Chicago Ridge
- Fadi AldaasChicago Ridge$18K
- Dinas AleksonisChicago Ridge$4K
- Eyad KarzounChicago Ridge$3K
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
- John RickelmanQuincy$90K
- Abbas Al-QamariChicago$40K
- Husam NayefPalos Park$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.